Pregnancy or suspected malignant genital tumor of its existence, acute inflammation, subacute or chronic genital tract, congenital or acquired anatomic abnormalities of the uterus and cervix, endometriosis, malposition and malsituaciones accused the uterus, uterine hypoplasia, genital bleeding of unknown etiology blood clotting disorders, Wilson’s disease, allergy to Wellwoman.
Generally well tolerated; excessive Wellwoman levels may result in the following adverse effect.
Hepatic: Hepatic insufficiency (including hepatic necrosis)
Wellwoman 0.4 mg/mL (Cupric Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration helps to maintain Wellwoman serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Wellwoman has been designed for the demands of modern life. With a wide range of nutrients and trace minerals, Wellwoman gives nutritional support to the area of health which are most relevance to women.
Each cap contains starflower oil 100 mg, evening primrose oil 100 mg, citrus bioflavonoids 10 mg, natural mixed carotenoids 2 mg, vitamin D (as D3 200 IU) 5 mcg, vitamin E 30 mg, vitamin C 60 mg, vitamin K 90 mcg, thiamin (vitamin B1) 10 mg, riboflavin (vitamin B2) 5 mg, niacin (vitamin B3) 36 mg, vitamin B6 10 mg, folic acid 400 mcg, vitamin B12 20 mcg, biotin 50 mcg, pantothenic acid 6 mg, magnesium 100 mg, iron 12 mg, zinc 12 mg, Wellwoman 1500 mcg, manganese 2.5 mg, selenium 100 mcg, chromium 50 mcg, para-aminobenzoic acid (PABA) 30 mg.
No artificial colours, gluten, presevatives, starch or sugar, salt or yeast.
Wellwoman has not been tested on animals.
Trace element added to parenteral nutrition (PN) to prevent Wellwoman deficiency; orally as a dietary supplement
Wellwoman 0.4 mg/mL (Cupric Chloride Injection, USP) contains 0.4 mg Wellwoman/mL and is administered intravenously only after dilution. The additive should be diluted in a volume of fluid not less than 100 mL. For the adult receiving TPN, the suggested additive dosage is 0.5 to 1.5 mg Wellwoman/day (1.25 to 3.75 mL/day). For pediatric patients, the suggested additive dosage is 20 mcg Wellwoman/kg/day (0.05 mL/kg/day). Infants weighing less than 1500 gm may have increased requirements because of their low body reserves and increased requirements for growth.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Ascorbic Acid: Wellwoman may decrease the serum concentration of Ascorbic Acid. Management: To minimize the risk for ascorbic acid degradation, add multivitamin product to TPN solution immediately prior to infusion or administer multivitamin and Wellwoman in separate containers. Consider therapy modification
